Gardasil
The Gardasil litigation was centralized before Judge Kenneth D. Bell in the Western District of North Carolina in August 2022, consolidating claims that the HPV vaccine caused autoimmune conditions, premature ovarian failure, postural orthostatic tachycardia syndrome, or other adverse health effects in recipients. With just 6 of 258 total filed actions still pending, the docket has moved from an initial filing population of meaningful size down to a small residual population — a sharp attrition pattern relative to many mass torts at a comparable age.
What likely drove that attrition is not disclosed by the pending-action count itself, but docket-wide reductions of this magnitude in a vaccine-injury or pharmaceutical products-liability MDL typically follow either an adverse general-causation ruling that narrowed which claims could proceed, a settlement program that resolved the bulk of filed claims, or a combination of both. Whichever mechanism applies here, the practical result is that the central liability questions this docket was centralized to resolve have, for the great majority of the original claim population, already been answered.
For the small number of actions still pending, resolution risk is now a case-specific question: understanding why a given claim was not resolved along with the rest of the docket, and what procedural posture — a later diagnosis, an opt-out, or a distinct legal theory — explains its survival. Criterica Intelligence's platform is built to surface exactly this kind of phase-transition signal across every active MDL: recognizing when a docket has moved from an open, developing liability question into a terminal phase where the remaining population requires individualized, rather than docket-wide, analysis. A companion capital brief on this docket is available through Criterica Capital.
It consolidates claims that the HPV vaccine Gardasil caused autoimmune conditions, premature ovarian failure, postural orthostatic tachycardia syndrome, or other adverse health effects in recipients.
A reduction of this scale in a vaccine-injury or pharmaceutical MDL typically follows an adverse general-causation ruling, a settlement program resolving most filed claims, or a combination of both, though the specific mechanism isn't disclosed by the pending count alone.
For the great majority of the original claim population, yes — the sharp attrition suggests the central causation and liability questions have already been answered for most claims, leaving only case-specific questions for what remains.
Understanding why each remaining claim was not resolved along with the rest of the docket — whether due to a later diagnosis, an opt-out, or a distinct legal theory — which requires individualized rather than docket-wide analysis.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.